Charles River Laboratories Intl. Inc vs VanEck Junior Gold Miners — how do they compare? Charles River Laboratories Intl. Inc trades at $301.4 (market cap $14.23B), while VanEck Junior Gold Miners trades at $114.43 (market cap $8.22B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, VanEck Junior Gold Miners nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and VanEck Junior Gold Miners for 41 Days on average.
| CRL | GDXJ | |
|---|---|---|
Market Cap | $14.23B | $8.22B |
Volume | 1,176,885 | 3,212,198 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $310.77 | $156.19 |
52-Week Low | $149.93 | $87.56 |
Typical Hold Time | 33 Days | 41 Days |
Enterprise Value | $17.06B | — |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.
The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.
GDXJ, the VanEck Junior Gold Miners ETF, trades at $114.43, up 4.85% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF is undergoing significant rebalancing, with multiple junior mining companies like Sinda Ltd. and Hemlo Mining Corp. being added to the fund as of September 2026, which may impact liquidity and composition. Key financial ratios are not applicable as this is an ETF tracking a basket of stocks.
The outlook is mixed; recent gold price strength above $4,400 (24/7 Wall Street, August 16, 2026) supports miner ETFs, but GDXJ's bearish technicals and institutional selling (Amundi reduced its stake by 50.5% as per Defense World, August 6, 2026) suggest caution. Risks include gold price volatility and the high-risk nature of junior miners. Investment appeal hinges on gold's momentum versus the ETF's technical weakness.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →